Blockade of vascular endothelial growth factor-A/receptor 2 exhibits a protective effect on angiotensin-II stimulated podocytes

XIANGCHUN LIU*, HONG ZHANG*, QUN WANG, KEZHOU YU, RONG WANG and JING SUN

Department of Nephrology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China

Received May 19, 2014; Accepted April 10, 2015

DOI: 10.3892/mmr.2015.3911

Abstract. Vascular endothelial growth factor (VEGF) and Angiotensin II (Ang-II) are important in glomerulosclerosis, which is one of the main causes of chronic kidney disease. Previous studies have demonstrated that angiotensin type 1 receptor blocker (ARB) can inhibit the synthesis of VEGF mediated by Ang-II and can effectively treat diabetic nephropathy. In the present study, the expression of VEGF and its receptors (VEGFR1/VEGFR2) was examined in Ang-II stimulated podocytes, which were treated with SU5416, a specific VEGFR2 inhibitor. The protein expression of synaptopodin, VEGFR1/2, phosphorylated VEGFR2 and extracellular signal-regulated kinases (ERK) was assessed by western blot analysis. The mRNA expression of transforming growth factor (TGF)-β1 was examined by reverse transcription-quantitative polymerase chain reaction. It was observed that Ang-II increased the expression of VEGF-A and VEGFR2. Simultaneously, the increased expression of phosphorylated (p-)VEGFR2 and p-ERK induced by Ang-II was downregulated by SU5416. SU5416 can decrease the expression of synaptopodin and increase the expression of TGF-β1 induced by Ang-II as well as ARB treatment. The expression of VEGFR1 remained unchanged by either Ang-II or SU5416 treatment. However, the normal podocytes administered SU5416 alone showed low levels of synaptopodin and high expression of TGF-β1 compared with the control. In conclusion, VEGF-A/VEGFR2 may be essential for podocytes in a normal state. It is suggested that blockade of VEGF-A/VEGFR2 may exhibit a protective effect on Ang-II stimulated podocytes.

Introduction

Chronic kidney disease (CKD) often begins with urinary protein loss (proteinuria), an early sign of kidney injury that constitutes a risk factor for further progressive destruction of the kidney. Proteinuria stems from injury to podocytes. Loss of podocytes or failure of podocyte function contributes to the development of glomerulosclerosis, which is the final stage of various renal diseases (1). A study demonstrated that there may be a close association between vascular endothelial growth factor (VEGF) and proteinuria (2). VEGF is an important regulator of angiogenesis. In addition, podocytes are the major source of VEGF production in the glomerulus (3,4). The VEGF family incorporates five ligands that can bind differentially to three receptor tyrosine kinases (VEGFR-1, -2 and -3). Recent studies have demonstrated that plasma VEGF levels are increased in CKD and podocyte-derived VEGF is upregulated in the early stages of diabetic nephropathy (5-7). The therapeutic effects of anti-VEGF strategies were partially shown to prevent albuminuria in diabetic rodents and prevent the complications of CKD (8-11). It was reported that primary or secondary elevations in VEGFR-1 (sFlt-1) may lead to decreased tissue levels of VEGF-A and the organ defects observed in preeclampsia (12). By contrast, Eremina et al (13) demonstrated that VEGF production by podocytes is also required to maintain the integrity of the glomerular basement membrane once fully formed, as pharmacologic and genetic inhibition of VEGF in mature podocytes resulted in glomerular endothelial cell damage and thrombotic microangiopathy (13).

From existing literature, the role of VEGF production by podocytes is well established; however, the expression and/or function(s) of VEGF receptors within the podocyte is less clear and is an area of discussion. It is also unclear whether VEGF can directly affect podocytes or is central to the pathogenesis of proteinuria. The aim of the present study was to identify the role of VEGF and its receptors in podocytes.

Materials and methods

Antibodies and reagents. The following commercially available antibodies were used: Anti-β-actin (cat. no. sc-8432), anti-synaptopodin (cat. no. sc-50459), anti-VEGFR1 (cat. no. sc-271789), anti-phosphorylated-VEGFR2 (cat. no. sc-16629), anti-VEGFR2 (cat. no. sc-6251) and
horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin G secondary antibody (cat. no. sc-358918; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), horseradish peroxidase-conjugated anti-rabbit secondary antibody (cat. no. sc-2007; Santa Cruz Biotechnology, Inc.) anti-phosphorylated-extracellular signal-regulated kinases (ERK; Cell Signaling Technology Inc., Beverly, MA, USA). SU5416 an inhibitor of VEGFR2 was obtained from Pfizer Inc. (New York, NY, USA). A bicinchoninic acid (BCA) protein assay kit and nitrocellulose membranes were obtained from Bio-Rad (Hercules, CA, USA). ELISA for the Quantikine mouse VEGF-A immunoassay was purchased from R&D Systems (Minneapolis, MN, USA). A RNAeasy Mini kit was obtained from Qiagen (Hilden, Germany).

Cell cultures. A thermosensitive, SV40-transfected immortalized mouse podocyte cell line was provided by Dr Peter Mundel (Mount Sinai School of Medicine, New York, NY, USA). The conditionally immortalized mouse podocytes carry a temperature-sensitive variant of the SV-40 large T antigen (tsA58) that is stimulated by mouse interferon (IFN)-γ and is stable at 33°C as described previously (14). At 33°C, cells were left to proliferate in RPMI-1640 medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10-20 U/ml mouse recombinant IFN-γ (Peprotech, Rocky Hill, NJ, USA) 100 U/ml penicillin/streptomycin (Sigma-Aldrich) and 10% fetal calf serum (FCS; Fuzhou Maixin Biotechnology Development Co., Ltd., Fuzhou, China). To induce differentiation, cells were thermoshifted to 37°C for two weeks without IFN-γ. These cells showed an epithelial morphology with a polyhedral shape and were detected by synaptopodin, a differentiated podocyte-specific marker, using immunofluorescence staining (Fig. 1A) (15).

Experimental design. Stimulation experiments were performed with Angiotensin II (Ang-II; Fuzhou Maixin Biotechnology Development Co., Ltd.). Ang-II concentrations (10-5, 10-6, 10-7 and 10-8 M) resulting in significant VEGF-A activation were used for time course experiments (24, 36, 48 and 60 h). The synchronized differentiated podocytes were either untreated or treated with Ang-II (10-7 M) for 48 h to achieve a podocyte injury pattern. To define the effect of the angiotensin type 1 receptor blocker (ARB), irbesartan (10-4 M; Sigma-Aldrich), or a VEGF receptor 2 inhibitor, SU5416, on Ang-II-stimulated podocytes (16,17), these two compounds were added to podocytes 1 h prior to treatment with Ang-II. All experimental groups were collected for extraction of total RNA and protein after exposure to experimental conditions for 48 h. Three independent experiments were performed.

ELISA. VEGF-A concentrations were measured in the supernatant of podocytes by ELISA using a Quantikine human VEGF-A Immunoassay. The supernatant was left on cells for 48 h. All experiments were performed in three independent experimental setups.

Immunofluorescent staining. Differentiated mouse podocytes were seeded on collagen I-coated glass coverslips (Shanghai Precision & Scientific Instrument Co., Ltd., Shanghai, China) for two weeks at 37°C, washed three times in 1X phosphate-buffered saline (PBS) for 5 min, then fixed with 4% formaldehyde for 30 min at 37°C and rinsed with PBS. Subsequently, 0.2% Triton X-100 (Sigma-Aldrich) in PBS was added for 20 min to permeabilize the cells. Podocytes on glass coverslips were washed with PBS again, blocked with 2% FCS at 37°C, then incubated with an anti-mouse synaptopodin antibody in 1:200 dilution at 4°C overnight. Cells were then washed with PBS and incubated with secondary antibody in the dark for 30 min at room temperature. Photomicrographs of each section of the groups were observed at x100 magnification with a fluorescence microscope (BX61; Olympus Corporation, Tokyo, Japan).

Western blot analysis. Podocytes from five experimental groups (control, Ang-II, SU5416, Ang-II + SU5416, and Ang-II + irbesartan) were collected and total protein concentration was measured using a BCA protein assay kit. Protein (30 µg) was electrophoresed on 5% SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane was blocked in 5% non-fat milk in Tris-buffered saline/0.15% Tween-20 (TBST) for 2 h at room temperature and hybridized overnight at 4°C with one of the primary antibodies. After three washes in TBST, membranes were incubated with the secondary antibody for 1 h at room temperature. The specific protein band on membranes was detected by computer-assisted video densitometry and its density was measured by using the Image Reader LAS-4000 (Fujifilm Corp., Tokyo, Japan).

RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total mRNA was purified from differentiated mouse podocytes using an RNAeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA concentration was assessed by spectrophotometry at 260 and 280 nm. Total mRNA (1 µg) was used for reverse transcription to generate cDNA following a reported protocol (18). The reverse transcription kits were provided by Biotec Corp. (Beijing, China). The resulting cDNA was used as a template for PCR amplification. Next, cDNA was amplified with the following PCR specific primers: Sense: 5'-GCC TGG TCT ACA TAC AGA GTG AG-3' and antisense: 5'-TCT AGT CCT CAG ACC CAG TCA TA-3' for mouse transforming growth factor (TGF)-β1; and sense: 5'-GTC CCT CAC CCT CCC AAA AG-3' and antisense: 5'-GCT GCC TCA ACA CCT CAA CCC-3' for mouse β-actin. PCR conditions were as follows: Denaturation at 92°C for 2 min, 35 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec, and extension at 72°C for 30 sec, followed by final extension at 72°C for 10 min. The RT-qPCR products were run on a 2% agarose gel with ethidium bromide staining by electrophoresis. The predicted band sizes were 699 bp for TGF-β1 and 266 bp for mouse β-actin. The abundance of TGF-β1 mRNA was normalized to β-actin.

Statistical analysis. All data are presented as the mean ± standard error of the mean. Differences between groups were analyzed by a two-sample t-test or one-way analysis of variance using GraphPad Prism software version 3.03 (GraphPad Software, San Diego, CA, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

Ang-II induces the expression of VEGF-A in podocytes. The integrity of VEGF-A was demonstrated by stimulation of Ang-II in podocytes. Concentrations of $10^{-5}$, $10^{-6}$, $10^{-7}$, $10^{-8}$ and $10^{-9}$ M Ang-II were used for the dose response experiment. Treatment with $10^{-7}$ M Ang-II led to a strong activation of VEGF-A (increased 2.7-fold, P<0.001, in three independent experiments) (Fig. 1A). In addition, time course experiments were performed to examine the time dependency of VEGF-A activation. Based on the dose-response experiments, $10^{-6}$, $10^{-7}$, and $10^{-8}$ M Ang-II were used for the time course experiments. VEGF-A peaked 48 h following stimulation with Ang-II (Fig. 1B). Thus, in the following experiments, a treatment dose of $10^{-7}$ M Ang-II for 48 h was used.

SU5416 is observed to ameliorate the decrease in the protein level of synaptopodin in Ang-II-injured podocytes. Following treatment with Ang-II ($10^{-7}$ M) for 48 h, the synchronized differentiated podocytes were injured. The protein level of synaptopodin in injured podocytes was significantly reduced (0.41±0.101 vs. 0.12±0.041, P=0.003) (Figs. 2 and 3). It was demonstrated that SU5416 restored the protein level of synaptopodin for blockade of VEGFR2, which was demonstrated by immunofluorescence (Fig. 2) and western blot analysis (0.12±0.041 vs. 0.33±0.084, P=0.002; Fig. 3). Compared with the control, the expression of synaptopodin was decreased in
LIU et al: PROTECTIVE EFFECT OF VEGF-A/VEGFR2 ON PODOCYTES

4343

the normal podocytes treated with SU5416 alone (0.41±0.101 vs. 0.21±0.092, P=0.008; Fig. 2).

In order to evaluate whether ARBs have beneficial effects on injured podocytes, 10^{-4} M irbesartan was added to Ang-II treated podocytes for 48 h. It was observed that irbesartan also partially restored the protein level of synaptopodin (0.12±0.041 vs. 0.31±0.117, P=0.013; Figs. 2 and 3).

SU5416 decreases TGF-β1 mRNA expression in Ang-II-injured podocytes. It was then examined whether blocking the VEGF/VEGFR2 pathway effects TGF-β1, a cytokine involved in extracellular fibrosis. Thus, SU5416 (1 µmol/l) was added to Ang-II injured podocytes for 48 h in order to analyze TGF-β1 mRNA expression. RT-qPCR revealed that the high expression of TGF-β1 mRNA in Ang-II-injured podocytes was decreased by SU5416 through the blockade of VEGFR2 (0.98±0.211 vs. 0.62±0.146, P=0.011; Fig. 4). Furthermore, it was observed that 10^{-4} M irbesartan reversed the expression of TGF-β1 mRNA in injured podocytes (0.98±0.211 vs. 0.65±0.134, P=0.019). In the normal state, treatment with SU5416 alone showed the same effect on TGF-β1 as Ang-II ("P=0.012, compared with the NC group).

Ang-II exhibits no effect on VEGF receptor expression. In addition to the expression of synaptopodin and TGF-β1, the expression of two major VEGF-A receptors VEGFR1 (flt-1) and VEGFR2 (flk-1) were investigated following treatment with Ang-II and SU5416. The VEGFR2 (flk-1) level was enhanced markedly by Ang-II stimulation compared with control as observed using western blot analysis (1.39±0.327 vs. 0.78±0.246, P=0.024). By contrast, VEGFR1 (flt-1) levels were not affected by treatment with Ang-II and SU5416 (P>0.05; Fig. 5).

SU5416 downregulates the phosphorylation of VEGFR2 and ERK. Based on the results that demonstrated that the expression of VEGFR2 was enhanced by Ang-II, the level of phosphorylated VEGFR2 and its downstream factor, ERK, were examined. It was observed that the expression of phosphorylated VEGFR2 was significantly increased by Ang-II, and was decreased by SU5416. Compared with control, phosphorylation of ERK was also upregulated by treatment with Ang-II. Blockade of VEGFR2 decreased the level of phosphorylated-ERK (Fig. 6).

Irbesartan showed the same effect on the phosphorylation of VEGFR2 and ERK as SU5416 (Fig. 6).

SU5416 decreases TGF-β1 mRNA expression in Ang-II-injured podocytes. It was then examined whether blocking the VEGF/VEGFR2 pathway effects TGF-β1, a cytokine involved in extracellular fibrosis. Thus, SU5416 (1 µmol/l) was added to Ang-II injured podocytes for 48 h in order to analyze TGF-β1 mRNA expression. RT-qPCR revealed that the high expression of TGF-β1 mRNA in Ang-II-injured podocytes was decreased by SU5416 through the blockade of VEGFR2 (0.98±0.211 vs. 0.62±0.146, P=0.011; Fig. 4). Furthermore, it was observed that 10^{-4} M irbesartan reversed the expression of TGF-β1 mRNA in injured podocytes (0.98±0.211 vs. 0.65±0.134, P=0.019). In the normal state, treatment with SU5416 alone showed the same effect on TGF-β1 as Ang-II ("P=0.012, compared with the NC group).

Ang-II exhibits no effect on VEGF receptor expression. In addition to the expression of synaptopodin and TGF-β1, the expression of two major VEGF-A receptors VEGFR1 (flt-1) and VEGFR2 (flk-1) were investigated following treatment with Ang-II and SU5416. The VEGFR2 (flk-1) level was enhanced markedly by Ang-II stimulation compared with control as observed using western blot analysis (1.39±0.327 vs. 0.78±0.246, P=0.024). By contrast, VEGFR1 (flt-1) levels were not affected by treatment with Ang-II and SU5416 (P>0.05; Fig. 5).

SU5416 downregulates the phosphorylation of VEGFR2 and ERK. Based on the results that demonstrated that the expression of VEGFR2 was enhanced by Ang-II, the level of phosphorylated VEGFR2 and its downstream factor, ERK, were examined. It was observed that the expression of phosphorylated VEGFR2 was significantly increased by Ang-II, and was decreased by SU5416. Compared with control, phosphorylation of ERK was also upregulated by treatment with Ang-II. Blockade of VEGFR2 decreased the level of phosphorylated-ERK (Fig. 6).

Irbesartan showed the same effect on the phosphorylation of VEGFR2 and ERK as SU5416 (Fig. 6).
Discussion

Recently, studies have shown that modulating angiogenesis-related factors has potential therapeutic effects in CKD (19-21). In the present study, the increased expression of VEGF-A was observed in cultured podocytes stimulated with Ang-II. Ang-II was observed to increase the expression of VEGFR2 (flk-1) and its level of phosphorylation; however, it had a lower effect on VEGFR1 (flt-1). Blockade of VEGFR2 by SU5416 downregulated the phosphorylation of VEGFR2 and ERK. Simultaneously, it recovered the expression of synaptopodin and decreased the level of TGF-β1 in Ang-II-induced podocytes. It was also demonstrated that the normal podocytes were injured by treatment with SU5416 alone. Irbesartan showed the same effect on the Ang-II stimulated podocytes as SU5416.

VEGF-A is required for the development of the glomerular filtration barrier (22). Although a previous study (22) established a link between increased VEGF-A, and glomerular injury and proteinuria, it remains unknown whether increased VEGF-A is causative or simply a consequence of these pathologic processes. There remains controversy regarding the beneficial and deleterious effects of VEGF-A on the kidney as certain studies suggested that VEGF may protect against renal injury (7,8). In the present study, it was observed that blockade of VEGF-A/VEGFR2 may injure podocytes, suggesting that VEGF-A/VEGFR2 is essential for the normal growth of podocytes. When the expression of VEGF-A/VEGFR2 was lower than the normal level, the podocytes were damaged. This is consistent with the findings of Eremina et al (13).

Simultaneously increased VEGF-A expression was observed in Ang-II-stimulated podocytes. Blockade of VEGFR2 was shown to reduce the phosphorylation of VEGFR2 and ERK, and ameliorate the change in expression of synaptopodin and TGF-β1. Thus, VEGF-A autocrined by podocytes treated with AngII may have an important effect on the extracellular matrix (ECM) and cell morphology through VEGFR2. Simultaneously, it may be postulated that the proportion balance of phosphorylated VEGFR2 has been broken when the podocytes is injured by Ang-II. Hohenstein et al (23) found that the majority of cells at sites of prominent injury, such as crescents, demonstrated high expression levels of VEGFR1 in a large number of renal biopsies from patients with glomerulonephritis (GN). However, numerous glomeruli had less intense VEGFR1 expression, despite obvious morphological changes such as increased cellularity or matrix. By contrast podocytic VEGFR2 expression was more prominent in biopsies with GN. The results of the present study showed that VEGFR1 had not been influenced by Ang-II and suggested that blockade of VEGFR2 had a beneficial effect on Ang-II-stimulated podocytes. It could be deduced that the roles of VEGFR1/2 were different in podocytes. While VEGFR1 may be important in cell proliferation and survival, VEGFR2 appeared to be involved in the podocytes architecture and morphology. When phosphorylation of VEGFR2 was impaired, cytokines involved in morphology and matrix, such as synaptopodin and TGF-β1 exhibited altered levels of expression. These data reveal that VEGF-A activation of VEGFR2, not VEGFR1, directly resulted in the damage of podocyte ECM and morphology by Ang-II.

To identify the mechanisms by which VEGF-A activated of VEGFR2 in stimulated Ang-II-injured podocytes, VEGF-A-induced signaling pathways were analyzed by blockade of VEGF-A/VEGFR2 using SU5416. It was shown that VEGF-A/VEGFR2 activation in Ang-II-injured podocytes stimulated phosphorylation of ERK. To the best of our knowledge, phosphorylation of ERK is the upstream regulator of TGFβ1. Thus, this suggested that the phosphorylation of ERK was required for the VEGF-A/VEGFR2-induced damage of podocytes treated with Ang-II.

Synaptopodin, an actin-associated protein, is expressed only in completely differentiated podocytes and in the telencephalic synapses (24). Podocytes are important in the maintenance of renal glomerular function and in the pathogenesis of glomerulosclerosis (25). It is postulated that synaptopodin modulates the actin-based contractile microfilament apparatus of the podocyte foot processes and the integrity of matured podocytes. Synaptopodin may be involved in the development of proteinuric renal diseases and maintenance of the glomerular filtration barrier (26,27). The increasing level of synaptopodin in podocytes has been revealed with proteinuria (28). The present study examined that blockade of VEGF-A/VEGFR2 by the VEGFR2 inhibitor ameliorated the decrease in the protein level of synaptopodin in Ang-II-injured podocytes. This result is in line with anti-VEGF-related proteinuria in non-diabetic CKD (29).

Although it is now evident that damage is transmitted from podocyte to podocyte, and from podocyte to other glomerular cells, it remains largely unknown how these transmissions occur, and what factors are involved (30). Possible mechanisms include increased toxic substance(s) secreted in an autocrine or paracrine manner, such as basic fibroblast growth factor, TGF-β, Ang-II and macrophage migration inhibitory factor, and decreased levels of supportive substances for survival of the podocytes. In the present study it was observed that inhibition of VEGF-A/VEGFR2 increased the expression of TGF-β1 mRNA in Ang-II-injured podocytes, indicating that blockade of the VEGF pathway may delay the progression of glomerulosclerosis. The observation that blockade of VEGF-A/VEGFR2 was associated with decreased expression of TGF-β1 mRNA suggested that podocyte damage may induce further podocyte damage in a positive feedback mechanism, which drives local spread of glomerulosclerosis.

Renin-angiotensin system (RAS) inhibitors have been shown to reduce glomerular permeability and proteinuria. Local elevations in Ang-II signaling mediated by angiotensin type I receptors led to elevations in VEGF expression in endothelial cells in rats (31). Several studies have demonstrated a close correlation between RAS and the level of VEGF in vitro, showing that Ang-II can induce VEGF expression (32-34). In the present study, the therapeutic effects of VEGFR2 inhibition on TGF-β1 and synaptopodin were observed compared with ARB in cultured podocytes. It was shown that pretreatment with irbesartan lowered the expression of TGF-β1, which is a major mediator of the hypertrophic and prosclerotic changes in the kidney. Furthermore, the results
suggested another anti-albuminuric molecular mechanism of irbesartan, which restored the levels of synaptopodin in Ang-II-injured podocytes.

In conclusion, the pathway of VEGF-A/VEGFR2 is essential for podocytes in the physiological state. The expression of VEGF-A and VEGFR2 was increased in Ang-II-injured podocytes. The VEGFR2 inhibitor appeared to restore the level of synaptopodin and decrease the expression of TGF-β1. It suggested that blockade of VEGF-A/VEGFR2 exhibits beneficial effects on the extracellular matrix and cell morphology in Ang-II-stimulated podocytes.

References